Arrowhead Asks to Test New Cancer Drug

By Associated Press
March 13, 2008
Comment (0)
Recommended (0)

Arrowhead Research Corp. said Thursday its Calando Pharmaceuticals subsidiary has asked the Food and Drug Administration for permission to start an early stage trial of a cancer drug candidate.

Calando Pharmaceuticals wants to begin an early clinical trial of the drug, designated CALAA-01. The main goals of early stage clinical trials, called Phase I studies, are designed to find out if a drug is safe and if it has any serious side effects.

CALAA-01 is an RNA interference drug designed to stop diseases by finding the genes that cause them, and turning them off. Calando wants to test the drug on patients with tumors that have either metastasized or cannot be removed by surgery.

The stock added 5 cents, or 2 percent, to $2.51 in afternoon trading.
Comment (0)
Recommended (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 597990, ~/articles/articlehandler.aspx, 9/5/2008 1:02:05 PM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Related Tickers

Arrowhead Research Corp

ARWR Down! $1.63 -0.02 (-1.21%) 12:42 PM
CAPS Rating:
103 Outperforms
10 Underperforms
Rate This Stock
Related Articles about ARWR
Articles mentioning ARWR

Major Indices

S&P 5001,231.72 -0.41%
DJIA11,170.89 -0.16%
RSL 2K708.83 -1.36%
NASD2,245.32 -0.61%
Updated: 12:46:17 PM
Sponsored by:

The Motley Poll

Where will the U.S. dollar go from here?

Sponsored by: